Angela Mastronuzzi, Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital and President of AIEOP, shared a post on LinkedIn:
” ’31I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future’ – just published with ESMO – European Society for Medical Oncology
31I-mIBG therapy plus melphalan is confirmed to be effective to reduce/control tumour burden. Further studies are needed to clarify the role and timing of this treatment and to integrate its role in the strategy of CAR-T cells.”
“131I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future”
Authors: M.A. De Ioris et al.
